Common Contracts
17 similar Underwriting Agreement contracts by Zogenix, Inc., Insys Therapeutics, Inc., River Valley Bancorp, others
GRANITE RIDGE RESOURCES, INC. (a Delaware corporation) 7,100,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 13th, 2023 • Granite Ridge Resources, Inc. • Crude petroleum & natural gas • New York
VELOCITY FINANCIAL, LLC [ ] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 6th, 2020 • Velocity Financial, LLC • Finance services • New York
SeaSpine Holdings Corporation 3,250,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 11th, 2018 • SeaSpine Holdings Corp • Surgical & medical instruments & apparatus • New York
IMMUNOMEDICS, INC. 11,500,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • June 15th, 2018 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New York
CHESAPEAKE UTILITIES CORPORATION 835,207 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 28th, 2016 • Chesapeake Utilities Corp • Natural gas transmisison & distribution • New York
Eagle Bancorp, Inc. (a Maryland corporation)Underwriting Agreement • August 1st, 2014 • Eagle Bancorp Inc • State commercial banks • New York
Eagle Bancorp, Inc. a Maryland corporation (the “Company”), confirms its agreement with Sandler O’Neill + Partners, L.P. (the “Underwriter”) with respect to the issue and sale by the Company, and the purchase by the Underwriter of the principal amount $70,000,000 aggregate principal amount of the Company’s 5.75% Notes due September 1, 2024 (the “Securities”). The Securities are to be issued pursuant to an indenture to be dated as of August 5, 2014 (the “Base Indenture”) between the Company and the Wilmington Trust, National Association, as trustee (the “Trustee”), as supplemented by a first supplemental indenture, to be dated as of August 5, 2014, between the Company and the Trustee (the “First Supplemental Indenture” and, together with the Base Indenture, the “Indenture”).
RIVER VALLEY BANCORP (an Indiana corporation) [·] Shares of Common Stock (No Par Value Per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • June 13th, 2014 • River Valley Bancorp • Savings institution, federally chartered • New York
RIVER VALLEY BANCORP (an Indiana corporation) [·] Shares of Common Stock (No Par Value Per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • May 29th, 2014 • River Valley Bancorp • Savings institution, federally chartered • New York
SUNDANCE ENERGY AUSTRALIA LIMITED AMERICAN DEPOSITARY SHARES REPRESENTING ORDINARY SHARES (NO PAR VALUE) UNDERWRITING AGREEMENTUnderwriting Agreement • February 20th, 2014 • Sundance Energy Australia LTD • Crude petroleum & natural gas • New York
ZOGENIX, INC. 26,666,667 Shares Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • November 6th, 2013 • Zogenix, Inc. • Pharmaceutical preparations • New York
Zogenix, Inc., a Delaware corporation (the “Company”), confirms its agreement with Stifel, Nicolaus & Company, Incorporated (“Stifel”), Leerink Swann LLC (“Leerink”) and each of the other Underwriters named in Schedule I hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Stifel and Leerink are acting as representatives (in such capacity, the “Representatives”), with respect to the issue and sale by the Company of 26,666,667 shares (the “Initial Securities”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of Initial Securities set forth in said Schedule I hereto, and with respect to the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of the 4,000,000 addi
BIOCRYST PHARMACEUTICALS, INC. 4,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • August 5th, 2013 • Biocryst Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
INSYS THERAPEUTICS, INC. Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 16th, 2013 • Insys Therapeutics, Inc. • Pharmaceutical preparations • New York
UNDERWRITING AGREEMENTUnderwriting Agreement • August 27th, 2012 • BNC Bancorp • National commercial banks • New York
BNC Bancorp, a North Carolina corporation (the “Company”), Bank of North Carolina (the “Bank”) and the United States Department of the Treasury (the “Selling Shareholder”) each confirms its agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated (“Merrill Lynch”) and Sandler O’Neill & Partners, L.P. (“Sandler O’Neill,” and collectively with Merrill Lynch, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 11 hereof), for whom Merrill Lynch and Sandler O’Neill are acting as Representatives (in such capacity, the “Representatives”), with respect to the sale by the Selling Shareholder and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of Fixed Rate Cumulative Perpetual Preferred Stock, Series A of the Company (the “Preferred Stock”) set forth in Schedule A hereto. The aforesaid 31,260 shares of Preferred Stock to be purchased by the Underwriters are referred to
ZOGENIX, INC. 32,500,000 Units Consisting of One Share of Common Stock and A Warrant to Purchase 0.45 of a Share of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 24th, 2012 • Zogenix, Inc. • Pharmaceutical preparations • New York
Zogenix, Inc., a Delaware corporation (the “Company”), confirms its agreement with Stifel, Nicolaus & Company, Incorporated (“Stifel”), Wells Fargo Securities, LLC (“Wells Fargo”) and each of the other Underwriters named in Schedule I hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Stifel and Wells Fargo are acting as representatives (in such capacity, the “Representatives”), with respect to the issue and sale by the Company of 32,500,000 units (the “Initial Securities”), each unit consisting of (i) one share (each, a “Share”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and (ii) a warrant to purchase 0.45 of a share of Common Stock (each, a “Warrant”), and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of Initial Securities set forth in said Schedule I hereto, and with respect to the grant by the Co
ZOGENIX, INC. 12,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 7th, 2011 • Zogenix, Inc. • Pharmaceutical preparations • New York
Zogenix, Inc., a Delaware corporation (the “Company”), confirms its agreement with Leerink Swann LLC (“Leerink”), Wells Fargo Securities, LLC (“Wells Fargo”) and each of the other Underwriters named in Exhibit A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Leerink and Wells Fargo are acting as representatives (in such capacity, the “Representatives”), with respect to the issue and sale by the Company of 12,000,000 shares (the “Initial Securities”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of Initial Securities set forth in said Exhibit A hereto, and with respect to the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of the 1,800,000 additiona
INSYS THERAPEUTICS, INC. Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 15th, 2011 • Insys Therapeutics, Inc. • Pharmaceutical preparations • New York
ZOGENIX, INC. Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • November 4th, 2010 • Zogenix, Inc. • Pharmaceutical preparations • New York
